1. Home
  2. LRMR

LRMR

Larimar Therapeutics Inc.

Logo Larimar Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-15-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Founded: N/A Country:
United States
United States
Employees: N/A City: BALA CYNWYD
Market Cap: 492.5M IPO Year: N/A
Target Price: $18.50 AVG Volume (30 days): 621.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.84 EPS Growth: N/A
52 Week Low/High: $2.18 - $13.68 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: